次要终点包括IRC评估的总生存期(OS)和总缓解率(ORR)。
Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC.
结果：FOXP3在肿瘤细胞中的表达与较差的总生存期有关，而且增加了FOXP3免疫染色强度。
Results: FOXP3 expression in tumors was associated with worse overall survival probability and the risk increased with increasing FOXP3 immunostaining intensity.
次要观察终点包括总生存期，安全性，患者对治疗设施的满意度和理解以及医疗资源的利用。
Secondary endpoints included overall survival, safety, patients' satisfaction with and perception of treatment convenience, and medical resource utilization.
欧美权威机构接受PFS作为观察终点，而非总生存期（OS），肾细胞癌作为贝伐单抗的适应症范围。
PFS, rather than overall survival (OS), was accepted by regulatory authorities in the United States and Europe as the endpoint for approval of bevacizumab for the renal cell carcinoma indication.
目的观察剂量密度化疗治疗乳腺癌的不良反应及对无病生存期和总生存期的影响。
Objective to investigate the adverse effect, disease free survival and overall survival of dose-dense chemotherapy in postoperative breast cancer patients.
生存中值反映了生存曲线上的一个时间点，并不能测量总的生存期。
Median survival reflects one time point along the survival curve and does not measure the overall survival benefit.
结论：我们对边缘区淋巴瘤的研究是已报道的研究中规模最大的之一，结论是边缘区淋巴瘤总体预后良好，中位总生存期超过19年。
Conclusions: In our MZL series, one of the largest reported, prognosis of MZL is good with a median OS of over 19 years.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
应用推荐